Recruiting NCT05621564
Pre-operative Therapy in Breast Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: pre-operative therapy.
- Who it may be relevant to
- Registry conditions: Breast Cancer. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Effect of Pre-operative Therapy on Response and Survival in Breast Cancer
Overview
This is a prospective and retrospective study to evaluate the effect of pre-operative therapy on response and survival, and compare the difference in response and survival by pre-operative regimen or by patient's clinicopathological characteristic in early or advanced breast cancer.
Interventions
- Drug pre-operative therapy
pre-operative therapy includes pre-operative chemotherapy, radiation, endocrine therapy, target therapy and other anti-tumor therapy
Primary outcome measures
- Pathologic Complete Response [Time frame: at surgery]
Secondary outcome measures (2)
- Objective response rate [Time frame: from the start of pre-operative treatment until the completion of surgery up to 6 months]
- Disease-free Survival [Time frame: From surgery until time of event up to 8 years]
Eligibility criteria
Inclusion criteria
- Female, Aged ≥18 years
- Histologically confirmed primary breast cancer
- Plan to receive pre-operative therapy
- Adequate organ function
Exclusion criteria
- History of neurological or psychological disease, including epilepsy or dementia
- Not suitable to participate in this study judged by investigators
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Renji Hospital, School of Medicine, Shanghai Jiaotong University — Shanghai
Publications
- Chen X, Zhao Y, Wang Y, Ye Y, Xu S, Zhou L, Lin Y, Lu J, Yin W. Serum lipid ratios as novel prognostic biomarkers for patients with locally advanced breast cancer treated with neoadjuvant therapy. Postgrad Med. 2024 Jun;136(5):541-550. doi: 10.1080/00325481.2024.2370235. Epub 2024 Jun 24. PMID 38912905
Identifiers
NCT: NCT05621564 · LY2022-028-B